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Abstract. PK/PD modelling will play an increasingly important role in drug development, because it will
identify key properties of a drug in vivo, allowing the characterization and prediction of the time course
of drug effects under physiological and pathological conditions (intensity and duration). It has developed
from a descriptive to a mechanism-based approach, taking the relevant processes on the causal path
between drug administration and drug effect into account. Recent developments and insights from
systems biology and systems pharmacology will provide new information on the complexities of disease
associated with the identiﬁcation of multiple targets for drug treatment. This will give rise to new
opportunities of drug combinations, which can only be developed rationally through the appropriate
application of dynamical systems-based PK/PD models.
KEY WORDS: mechanism-based PK/PD models; new drug combinations; PK/PD modeling in drug
development; systems pharmacology and therapeutics.
BACKGROUND
In the past 25 years much progress has been made in the
ﬁeld of integrated pharmacokinetic–pharmacodynamic (PK/
PD) modelling and its application, as can be deduced from
the considerable increase in the number of papers in this area
published in pharmaceutical and clinical pharmacological
journals. This holds both for the modelling aspects per se as
well as for its applications in drug development and research
on medicines in general. This progress in PK/PD becomes
actually also very clear from the Proceedings and Abstracts of
the Symposia that LACDR at Leiden/University has orga-
nized every 4 years since 1990 under the theme “Measurement
and Kinetics of in vivo Drug Effects. Advances in simultaneous
PK/PDmodelling” (1). Dr. Meindert Danhof has always been
the principal organizer, each time assisted by key contributors
to the ﬁeld like Drs. Gerhard Levy, Lewis Sheiner, Carl Peck,
Jean-Louis Steimer, Don Stanski, Mats Karlsson, Jaap
Mandema, Piet-Hein van der Graaf, Bob Powell, Nick Holford
and Paul Rolan. The interest for these symposia has consider-
ably increased over the years with contributions from acade-
mia as well as from industry, illustrating the recognition of the
relevance of PK/PD modelling in drug development. In 1997
we summarized this in a paper with the typical Dutch subtitle
“The wooden shoe paradigm” (2). It emphasized that PK/PD
should be the steering mechanism throughout the drug devel-
opment process in order to obtain the information relevant to
be put into the drug label. Furthermore it stated that col-
laboration between the industry, academia and regulatory
agencies should be necessary to achieve this. This call for
more cooperation was repeated in the FDA Report in 2004
on: “Innovation or Stagnation. Challenge and Opportunity on
the CriticalPath to New Medical Products” (3). The critical
path has to become more innovative and more informative in
order to assure that novel medicines will be more effective
and safer than existing ones and by necessity take the
important issue of “personalized medicine” into account.
Integrated PK/PD modelling is a most relevant tool to
achieve this and should be considered and implemented at
the earliest phases of drug development (4). Also in drug
delivery research PK/PD is to become an important aspect in
order to assure that advanced drug delivery systems represent
added therapeutic value (5).
CURRENT PK/PD MODELLING APPROACHES
The primary objective of PK/PD modelling is to identify
key properties of a drug in vivo, which allows the character-
ization and prediction of the time course of drug effects under
physiological and pathological conditions (intensity and
duration). In the early pioneering studies (e.g. (6)), this was
attempted by a rather empirical approach where the model
comprised three components: a pharmacokinetic model,
characterizing the time course of drug and metabolite
concentrations in plasma; a pharmacodynamic model, char-
acterizing the relationship between concentration and effect(s);
a link model, which serves to account for the often observed
delay of the effect relative to the plasma concentration (e.g.
“effect compartment” model). Such models can successfully be
applied when the delay in effect is caused by drug distribution to
extracellular targets by passive diffusion. However, target
distribution kinetics may often be more complex, e.g. for drugs
acting on intracellular targets or with a site of action in organs
which are protected by speciﬁc barriers, e.g. the brain. This
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requires that the role of speciﬁc transporters, which either
increase or decrease the target-site concentration of the drug, is
taken into account. Physiologically-based PK modelling con-
cepts will be helpful to characterize and predict target-site
distribution kinetics in such situations.
In recent years a far more mechanism-based approach is
being pursued, which features speciﬁc expressions to charac-
terize processes on the causal path between drug administra-
tion and effect. These include: target site distribution (as
discussed), target binding and activation, pharmacodynamic
interactions (also with endogenous substances), transduction,
homeostatic feedback mechanisms and the effects of the drug
on disease progression. A most comprehensive review of this
mechanism-based PK/PD modelling has recently been pub-
lished by Danhof et al. (7), which also includes several
examples in which such an approach has successfully been
applied. A key feature of this mechanism-based approach is
the explicit distinction between drug-specific properties and
biological system-specific properties. Drug-speciﬁc are those
that describe the interaction between the drug and the
biological system in terms of target afﬁnity and target
activation, whereas system-speciﬁc parameters describe the
functioning of the biological system per se. The distinction
between these two types of parameters appears to be crucial
for the prediction of drug effects in humans from in vitro and
animal experiments. Drug-speciﬁc properties like the in vivo
target afﬁnity and intrinsic efﬁcacy can often be predicted on
the basis of in vitro bioassays. The values for these properties
or parameters often appear to be identical between species,
implying that these may not require scaling when applied in
inter-species extrapolation. Moreover, there is no or lesser
need to take intra- and inter-individual variability in the
values of these parameters into consideration. These obser-
vations on drug-speciﬁc properties have been made for small
molecule drugs; it still is to be investigated if these hold for
biologicals (proteins, antibodies) as well. On the other hand,
biological system-speciﬁc parameters (e.g. the level of ex-
pression of the target protein or the rate constants of
processes at the level of transduction) can only be estimated
by in vivo systems analysis and usually their values will vary
between species, individuals, disease states and other con-
ditions. This implies that interspecies scaling of biological
system-speciﬁc parameters is required and that intra- and
inter-individual variability in these parameters must be taken
into account.
Preclinical investigations in suitable experimental animal
models (e.g. chronically instrumented ones) are most impor-
tant to explore and develop a suitable mechanism-based PK/
PD model. These often rely on the use of biomarkers
characterizing the processes on the causal path of drug effects
to the ultimate clinical effect. The important concept of
pharmacological transduction refers to the processes that
govern the transduction of target activation into drug
response in vivo. When such processes are slow in vivo
(operating at rate constants in the order of hours or even
days) they will determine the time course of drug effects.
Modelling of such processes is often complex because they
are typically non-linear. Furthermore complex homeostatic
feedback mechanisms may attenuate or alter drug response in
terms of ﬂuctuating effects with time, dependence of drug
effects on the rate of administration, tolerance development
upon continuous or chronic administration, or the occurrence
of rebound phenomena upon cessation of treatment. The
latter also is a very important issue to consider in relationship
to the often observed patient’s poor adherence to the
prescribed dosage regimen. Such time-dependent pharmaco-
logical transduction mechanisms require PK/PD modelling
concepts which are based on dynamical systems analysis. This
approach is also applied to the latest important and promising
development in PK/PD, i.e. the modelling of disease progres-
sion during drug treatment (7,8).
SYSTEMS BIOLOGY AND SYSTEMS THERAPEUTICS
The term dynamical systems analysis links PK/PD
modelling with a most important fundamental current devel-
opment in research in biology at large, i.e. that of “systems
biology”. During the past 25 years enormous progress has
been made in unravelling the (human) genome and high-
throughput and bio-informatics technologies have generated
an explosion of data at the level of the genome, the proteome
and the metabolome. However, this reductionistic approach
of generating important data on individual components of a
biological system is insufﬁcient to understand the functioning
of “life” at the cellular or organ level, let alone that at the
level of an entire living organism. Life functions through the
continuous and integrated dynamic interactions between
the numerous components of a systems network. Systems
biology is the branch of biology that aims at studying the
functioning of these networks and thereby provide an integrated
understanding of how life functions. In several countries all over
the world speciﬁc institutes have been established in recent
years to address this formidable multidisciplinary research
challenge, combining expertise from a large number of different
disciplines, including mathematics, physics, (bio)chemistry,
informatics, technical sciences and biology in all its aspects. An
essential central component of such research is the modelling
cycle: the iterative cycle of simulations, predictions, experimen-
tal veriﬁcation and new hypothesis generation (9). Through
such approaches ultimately key components, or interactions
between components, in a network of life may be identiﬁed,
which constitute normal physiology but also may explain the
development of pathophysiology. Once robust models have
been established, interventions like pharmacological ones, can
be tested in terms of attempting to attenuate speciﬁc compo-
nents of the network which may be associated with efﬁcacy or
safety of drug therapy. Of course these are enormously
complex approaches, but we will begin to learn more about
the multifactorial character of most diseases and thereby
realize that our current therapeutic practice of attempting to
cure a disease or alleviate its symptoms by one drug that more
or less speciﬁcally acts at one target in the biological system, is
very primitive and inadequate. Through systems biology and
systems pharmacology we are likely to identify a number of
different key targets in a disease, each of which may require
speciﬁc pharmacological intervention in order to achieve
optimal efﬁcacious and safe treatment. We know already at
this moment that different targets may have to be addressed in
order to achieve a better treatment and therefore the practice
of combination therapies is actually not uncommon in medical
practice (e.g. in asthma and hypertension). In the future
rational drug combinations will be designed on the basis of
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new insights in disease mechanisms including the speciﬁc com-
ponents of the biological systems underlying these. And in
order to do that rationally, PK/PD modelling will be an essen-
tial tool to evaluate such combinations in assessing their de-
sirable “additive” or “synergistic” effects. Already at this stage
PK/PD modelling has proved to be very useful in studying
drug–drug interactions (DDIs) in vivo (7,10). Currently DDIs
are usually considered as undesirable and cumbersome,
because they are associated with increased risks during com-
bined treatment. And ﬁxed drug combinations are rather the
exception than the rule in current therapeutic practice. How-
ever, this may well change in the future on the basis of new
insights in disease mechanisms, which require rationally de-
signed and developed ﬁxed drug combinations. This perspec-
tive represents exciting new opportunities for drug discovery
and development, which will include new chemical entities and
biologics, as well as existing molecules which have already
been used as medicines for a long time. “Systems therapeutics”
will be the result of this, with PK/PD modelling as the most
important scientiﬁc in vivo tool to assess its rationality. Of
course this also implies major challenges in clinical drug
evaluation, i.e. efﬁcacy and safety assessment (trial designs,
statistical analysis, identiﬁcation of adverse effects etc).
CONCLUSIONS
PK/PD modelling has developed from a descriptive to a
mechanism-based approach. In recent years novel concepts of
mechanism-based PK/PD modelling have been developed
and successfully applied and they potentially constitute a
basis for predicting drug effects in humans on the basis of
pertinent information from pre-clinical in vitro and in vivo
experimental data. It may be expected that when more
detailed information on the biological system becomes
available (i.e. on drug transporter function, pharmacological
receptor function and regulation, homeostatic feedback
mechanisms, disease progression), the accuracy of the pre-
dictions will further improve. PK/PD modelling thereby will
be a very important tool in efﬁcacy and safety assessment
during the drug development process of which it should
become an integral part as early as possible. New insights
derived from systems biology and systems pharmacology may
give rise to exciting new opportunities of rational drug
combinations, which can only be developed through the
appropriate application of dynamical systems-based PK/PD
models. It may well be that a new era of “systems therapeutics”
will subsequently evolve.
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